Novo Nordisk Goodwill and Intangible Assets 2010-2024 | NVO

Novo Nordisk goodwill and intangible assets from 2010 to 2024. Goodwill and intangible assets can be defined as the sum of all intangible asset fields
  • Novo Nordisk goodwill and intangible assets for the quarter ending September 30, 2024 were $8.032B, a 1.28% decline year-over-year.
  • Novo Nordisk goodwill and intangible assets for 2023 were $8.771B, a 20.47% increase from 2022.
  • Novo Nordisk goodwill and intangible assets for 2022 were $7.281B, a 6% increase from 2021.
  • Novo Nordisk goodwill and intangible assets for 2021 were $6.869B, a 117.04% increase from 2020.
Novo Nordisk Annual Goodwill and Intangible Assets
(Millions of US $)
2023 $8,771
2022 $7,281
2021 $6,869
2020 $3,165
2019 $875
2018 $787
2017 $505
2016 $403
2015 $321
2014 $246
2013 $288
2012 $258
2011 $278
2010 $260
2009 $194
Novo Nordisk Quarterly Goodwill and Intangible Assets
(Millions of US $)
2024-09-30 $8,032
2024-06-30 $8,009
2024-03-31 $8,684
2023-12-31 $8,771
2023-09-30 $8,136
2023-06-30 $7,414
2023-03-31 $7,275
2022-12-31 $7,281
2022-09-30 $6,349
2022-06-30 $6,376
2022-03-31 $6,536
2021-12-31 $6,869
2021-09-30 $3,255
2021-06-30 $3,286
2021-03-31 $3,300
2020-12-31 $3,165
2020-09-30 $1,478
2020-06-30 $854
2020-03-31 $862
2019-12-31 $875
2019-09-30 $750
2019-06-30 $889
2019-03-31 $807
2018-12-31 $787
2018-09-30 $719
2018-06-30 $672
2018-03-31 $666
2017-12-31 $505
2017-09-30 $413
2017-06-30 $391
2017-03-31 $397
2016-12-31 $403
2016-09-30 $427
2016-06-30 $320
2016-03-31 $319
2015-12-31 $321
2015-09-30 $218
2015-06-30 $216
2015-03-31 $208
2014-12-31 $246
2014-09-30 $249
2014-06-30 $314
2014-03-31 $309
2013-12-31 $288
2013-09-30 $299
2013-06-30 $286
2013-03-31 $277
2012-12-31 $258
2012-09-30 $247
2012-06-30 $250
2012-03-31 $259
2011-12-31 $278
2011-09-30 $278
2011-06-30 $285
2011-03-31 $272
2010-12-31 $260
2010-09-30 $221
2010-06-30 $203
2010-03-31 $210
2009-12-31 $194
2009-09-30 $192
2009-06-30 $167
2009-03-31 $160
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $481.063B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
AstraZeneca (AZN) United Kingdom $199.957B 17.81
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51